QP 03 - Right Care, Right Cost: Access and Utilization in Oncology

Presentations

• 05:00pm - 05:05pm ET

  Introductions

  Speaker: Onyinye Balogun, MD, MS - Weill Cornell Medicine/New York Presbyterian Brooklyn Methodist, Brooklyn
• 05:05pm - 05:10pm ET

  The Cost Effectiveness of Neoadjuvant FOLFIRINOX vs. Gemcitabine Based Chemoradiotherapy (CRT) for Resectable or Borderline-Resectable Pancreatic Ductal Adenocarcinoma

  Speaker: Nandita Kasireddy, - Geisel School of Medicine at Dartmouth, Lebanon
• 05:10pm - 05:15pm ET

  Cost-Effectiveness of Memantine for Patients Undergoing Whole Brain Radiation Therapy (WBRT)

  Speaker: Adam Kessel, MD - Mayo Clinic Rochester, Rochester
• 05:15pm - 05:20pm ET

  Impact of Hypofractionation on RVU Generation in Radiation Oncology

  Speaker: Nicholas Zaorsky, MD, MS - University Hospitals, Cleveland
• 05:20pm - 05:25pm ET

  A Cost-Effectiveness and Health Equity Analysis of Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer

  Speaker: Kritika Subramanian, MD, MS - Montefiore Medical Center/Albert Einstein College of Medicine, Bronx
• 05:25pm - 05:30pm ET

  Disease Site-Specific Risk Stratification for Acute Care Utilization In Radiation Oncology: A Large-Scale Competing Risk Analysis

  Speaker: Lavanya Pandey, BS - UCLA, Los Angeles
• 05:30pm - 05:35pm ET

  Relationship between Payer Organizational Stability and Radiation Oncology Treatment Timelines: A Time-Series Analysis

  Speaker: William Chen, MD - Northwell, New Hyde Park
• 05:35pm - 05:55pm ET

  Questions & Answers

  Speaker: Trevor Royce, MD, MS, MPH - Wake Forest School of Medicine Department of Radiation Oncology, Chapel Hill
• 05:55pm - 06:00pm ET

  Closing

  Speaker: Onyinye Balogun, MD, MS - Weill Cornell Medicine/New York Presbyterian Brooklyn Methodist, Brooklyn